GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Purchased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC grew its position in GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Rating) by 215.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,154 shares of the company’s stock after purchasing an additional 27,445 shares during the period. Tower Research Capital LLC TRC’s holdings in GoodRx were worth $187,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Light Street Capital Management LLC lifted its stake in shares of GoodRx by 10.0% in the 2nd quarter. Light Street Capital Management LLC now owns 4,629,276 shares of the company’s stock valued at $27,405,000 after purchasing an additional 420,123 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of GoodRx by 740.1% in the 2nd quarter. Renaissance Technologies LLC now owns 3,245,622 shares of the company’s stock valued at $19,214,000 after purchasing an additional 2,859,300 shares in the last quarter. BlackRock Inc. lifted its stake in shares of GoodRx by 5.8% in the 1st quarter. BlackRock Inc. now owns 1,110,156 shares of the company’s stock valued at $21,459,000 after purchasing an additional 60,979 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of GoodRx by 92.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 735,028 shares of the company’s stock valued at $3,433,000 after purchasing an additional 352,110 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of GoodRx by 4.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 581,820 shares of the company’s stock valued at $2,717,000 after purchasing an additional 24,595 shares in the last quarter. 35.22% of the stock is owned by institutional investors and hedge funds.

GoodRx Price Performance

GDRX stock opened at $5.50 on Wednesday. The company has a quick ratio of 12.05, a current ratio of 12.05 and a debt-to-equity ratio of 0.80. GoodRx Holdings, Inc. has a 52-week low of $3.82 and a 52-week high of $20.59. The stock’s 50 day moving average is $5.26 and its two-hundred day moving average is $5.24. The company has a market capitalization of $2.18 billion, a PE ratio of -78.56, a P/E/G ratio of 12.41 and a beta of 0.84.

Analysts Set New Price Targets

Several research firms have recently weighed in on GDRX. Credit Suisse Group reduced their price objective on GoodRx from $9.00 to $8.00 and set a “neutral” rating on the stock in a research note on Thursday, March 2nd. Royal Bank of Canada dropped their target price on GoodRx from $11.00 to $6.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 9th. Deutsche Bank Aktiengesellschaft raised their target price on GoodRx from $7.00 to $8.00 in a report on Tuesday. DA Davidson dropped their target price on GoodRx to $5.00 in a report on Tuesday, November 15th. Finally, Truist Financial dropped their target price on GoodRx to $6.00 in a report on Wednesday, November 16th. Thirteen equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.97.

GoodRx Profile

(Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.